MedTrace Logo

Phase II Study DCVAC/OvCa Added to First Line Carboplatin and Paclitaxel Newly Diagnosed Epithelial Ovarian Carcinoma

NCT02107937 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 136

Last updated 2022-05-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether DCVAC/OvCa added to chemotherapy (carboplatin plus paclitaxel as first line chemotherapy) may result in prolongation of progression free survival (PFS).

Conditions

  • Ovarian Neoplasms
  • Ovarian Epithelial Cancer

Interventions

BIOLOGICAL

DCVAC/OvCa with Standard of Care

DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel

BIOLOGICAL

DCVAC/OvCa sequentially chemotherapy

DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel

DRUG

Standard of Care

Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy

Sponsors & Collaborators

  • SOTIO a.s.

    lead INDUSTRY

Principal Investigators

  • Harald Fricke, MD, PhD · SOTIO a.s.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-11-30
Primary Completion
2020-11-30
Completion
2021-11-30

Countries

  • Czechia
  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02107937 on ClinicalTrials.gov